Suggested remit: To appraise the clinical and cost effectiveness of olaparib within its marketing authorisation for adjuvant treatment of high-risk HER2-negative, BRCA-positive early or locally advanced breast cancer after chemotherapy and surgery.
Status Awaiting development
Decision None selected
Process STA 2018
ID number 3893

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
29 October 2021 - 26 November 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual